Criterios para el uso e investigación de medicamentos off-label frente al covid-19 en Latinoamérica

Palabras clave: Pedagogía, Ivermectina, COVID-19, Educación médica, Off-label.

Resumen

La pandemia por COVID-19 representa una de los retos más importantes en materia de salud pública. La ausencia de evidencia científica sólida y la severidad del cuadro clínico han justificado el uso compasivo de medicamentos off-label. No obstante, el uso indiscriminado de estos medicamentos, sin un fundamento sólido por parte de los médicos puede representar un peligro para la salud de los pacientes.

Por otra parte, la comunidad médica y científica de Latinoamérica está llamada a evaluar hipótesis de investigación que mitiguen el impacto de la pandemia en nuestras poblaciones.

Tomando como ejemplo pedagógico el uso de la ivermectina, se proponen criterios como la plausibilidad biológica, la evidencia metodológica y estadísticamente aceptable, una respuesta clínica favorable, un perfil farmacológico seguro, la factibilidad y el interés altruista como sustento para el empleo de medicamentos offlabel durante la pandemia. Estos criterios posibilitarían un uso racional de medicamentos y priorizar en el contexto de una investigación las opciones terapéuticas posiblemente más efectivas.

Descargas

Los datos de descargas todavía no están disponibles.

Biografía del autor/a

Yeison Harvey Carlosama-Rosero, Universidad Cooperativa de Colombia

Universidad Cooperativa de Colombia. Facultad de Medicina. Grupo Interdisciplinario de Investigación en Salud y Enfermedad. Pasto, Colombia.

Referencias bibliográficas

Kupferschmidt K, Cohen J. Race to find COVID-19 treatments accelerates. Science 2020; 367:1412–3. Doi: 10.1126/science.367.6485.1412

WHO, UN Foundation and partners launch first-of-its-kind COVID-19 Solidarity Response Fund [Internet]. World Healt Organization. 2020 [Citado: mayo 06, 2020]. Disponible en: https://www.who.int/news/item/13-03-2020-who-unfoundation-and-partners-launch-first-of-its-kind-covid-19-solidarity-response-fund

Launch of a European clinical trial against COVID-19 [Internet]. Institut national de la santé et de la recherche médicale. 2020. [Citado: mayo 06, 2021]. Disponible en: https://presse.inserm.fr/en/launch-ofa-european-clinical-trial-against-covid-19/38737/

Kalil AC. Treating COVID-19—Off-Label Drug Use, Compassionate Use, and Randomized Clinical Trials During Pandemics. JAMA. 2020; 323(19):1897-8. doi:10.1001/jama.2020.4742

Ongoing Living Update of Potential COVID-19 Therapeutics: summary of rapid systematic reviews [Internet]. Pan American Health Organization. 2020. [Citado: mayo 08, 2020]. Disponible en: https://iris.paho.org/bitstream/handle/10665.2/52025/PAHOIMSCovid19200008_eng.pdf?sequence=1&isAllowed=y

Mehra MR, Desai SS, Ruschitzka F, Patel AN. RETRACTED: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. The Lancet. 2020: S0140-6736(20)31180-6. https://doi.org/10.1016/S0140-6736(20)31180-6

Paumgartten FJR, Oliveira ACAX de, Paumgartten FJR, Oliveira ACAX de. Off label, compassionate and irrational use of medicines in Covid-19 pandemic, health consequences and ethical issues. Ciênc Amp Saúde Coletiva. 2020; 25(9):3413–9. https://doi.org/10.1590/1413-81232020259.16792020

WHO COVID-19 Solidarity Therapeutics Trial [Internet]. World Healt Organization. 2020. [Citado: octubre 27, 2020]. Disponible en: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments

Manterola DC, Zavando MD. Cómo interpretar los “Niveles de Evidencia” en los diferentes escenarios clínicos. Rev Chil Cir. 2009; 61:582–95. https://doi.org/10.4067/S0718-40262009000600017

Tay MYF, Fraser JE, Chan WKK, Moreland NJ, Rathore AP, Wang C, et al. Nuclear localization of dengue virus (DENV) 1-4 non-structural protein 5; protection against all 4 DENV serotypes by the inhibitor Ivermectin. Antiviral Res. 2013; 99:301-6. https://doi.org/10.1016/j.antiviral.2013.06.002

Varghese FS, Kaukinen P, Gläsker S, Bespalov M, Hanski L, Wennerberg K, et al. Discovery of berberine, abamectin and ivermectin as antivirals against chikungunya and other alphaviruses. Antiviral Res. 2016; 126:117-24. https://doi.org/10.1016/j.antiviral.2015.12.012

Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020; 178:104787. https://doi.org/10.1016/j.antiviral.2020.104787

Petrosillo N, Viceconte G, Ergonul O, Ippolito G, Petersen E. COVID-19, SARS and MERS: are they closely related?. Clin Microbiol Infect. 2020; 26:729–34. https://doi.org/10.1016/j.cmi.2020.03.026

Frieman M, Yount B, Heise M, Kopecky-Bromberg SA, Palese P, Baric RS. Severe Acute Respiratory Syndrome Coronavirus ORF6 Antagonizes STAT1 Function by Sequestering Nuclear Import Factors on the Rough Endoplasmic Reticulum/Golgi Membrane. J Virol. 2007; 81:9812-24. https://doi.org/10.1128/JVI.01012-07

Billiau A. Interferon-gamma: biology and role in pathogenesis. Adv Immunol. 1996; 62:61–130. https://doi.org/10.1016/s0065-2776(08)60428-9

Kindler E, Thiel V. SARS-CoV and IFN: Too Little, Too Late. Cell Host Microbe. 2016; 19:139–41. https://doi.org/10.1016/j.chom.2016.01.012

Hernández-Avila M, Garrido-Latorre F, López-Moreno S. Diseño de estudios epidemiológicos. Salud Pública México. 2000; 42:144–54. https://doi.org/10.1590/S0036-36342000000200010

Veiga de Cabo J, Fuente Díez E de la, Zimmermann Verdejo M. Modelos de estudios en investigación aplicada: conceptos y criterios para el diseño. Med Segur Trab. 2008; 54:81-8

Silva-Aycaguer LC. Las pruebas de significación estadística: seis décadas de fuegos artificiales. Rev Fac Nac Salud Pública. 2016; 34 (3):372-9. https://doi.org/10.17533/udea.rfnsp.v34n3a11

Rajter JC, Sherman MS, Fatteh N, Vogel F, Sacks J, Rajter J-J. Use of Ivermectin Is Associated With Lower Mortality in Hospitalized Patients With Coronavirus Disease 2019. Chest Journal. 2020; 159(1):85-92. https://doi.org/10.1016/j.chest.2020.10.009

Ch JV. Ivermectina: Sus Múltiples Usos, Seguridad y Toxicidad. Educación Médica Continua. 2010; 26(4):358-368

Chandler RE. Serious Neurological Adverse Events after Ivermectin-Do They Occur beyond the Indication of Onchocerciasis?. Am J Trop Med Hyg. 2018; 98(2):382-8. https://doi.org/10.4269/ajtmh.17-0042

Lespine A, Dupuy J, Alvinerie M, Comera C, Nagy T, Krajcsi P, et al. Interaction of macrocyclic lactones with the multidrug transporters: the bases of the pharmacokinetics of lipidlike drugs. Curr Drug Metab. 2009; 10:272–88. https://doi.org/10.2174/138920009787846297

Kyelem D, Biswas G, Bockarie MJ, Bradley MH, El-Setouhy M, Fischer PU, et al. Determinants of success in national programs to eliminate lymphatic filariasis: a perspective identifying essential elements and research needs. Am J Trop Med Hyg. 2008; 79:480-4

Osei-Atweneboana MY, Eng JK, Boakye DA, Gyapong JO, Prichard RK. Prevalence and intensity of Onchocerca volvulus infection and efficacy of ivermectin in endemic communities in Ghana: a two-phase epidemiological study. The Lancet. 2007; 369(9578):2021-9. https://doi.org/10.1016/S0140-6736(07)60942-8

Momekov G, Momekova D. Ivermectin as a potential COVID-19 treatment from the pharmacokinetic point of view: antiviral levels are not likely attainable with known dosing regimens. MedRxiv. 2020.04.11.20061804. https://doi.org/10.1101/2020.04.11.20061804

Schmith VD, Zhou J, Lohmer LR. The Approved Dose of Ivermectin Alone is not the Ideal Dose for the Treatment of COVID-19. Clin Pharmacol Ther. 2020; 108(4):762-765. https://doi.org/10.1002/cpt.1889

Bray M, Rayner C, Noël F, Jans D, Wagstaff K. Ivermectin and COVID-19: A report in Antiviral Research, widespread interest, an FDA warning, two letters to the editor and the authors’ responses. Antiviral Res. 2020; 178:104805. https://doi.org/10.1016/j.antiviral.2020.104805

McCreary EK, Pogue JM. Coronavirus Disease 2019 Treatment: A Review of Early and Emerging Options. Open Forum Infect Dis. 2020; 7(4):ofaa105. https://doi.org/10.1093/ofid/ofaa105

Zhong M, Sun A, Xiao T, Yao G, Sang L, Zheng X, et al. A Randomized, Single-blind, Group sequential, Activecontrolled Study to evaluate the clinical efficacy and safety of α-Lipoic acid for critically ill patients with coronavirus disease 2019(COVID-19). MedRxiv. 2020:04.15.20066266. https://doi.org/10.1101/2020.04.15.20066266

Gritti G, Raimondi F, Ripamonti D, Riva I, Landi F, Alborghetti L, et al. Use of siltuximab in patients with COVID-19 pneumonia requiring ventilatory support. MedRxiv. 2020: 04.01.20048561. https://doi.org/10.1101/2020.04.01.20048561

Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review. JAMA. 2020; 323(18):1824-36. https://doi.org/10.1001/jama.2020.6019

Ahmed S, Johnson K. Operaciones bursátiles en Gilead por fármaco contra COVID-19 podrían llamar atención de reguladores [Internet]. Reuters. 2020. [Citado: noviembre 02, 2021]. Disponible en: https://www.reuters.com/article/salud-coronavirus-gileadidLTAKBN2382VS

Lupkin S. Remdesivir Priced At More Than $3100 For A Course Of Treatment [Internet]. National Public Radio. 2020. [Citado: octubre 27, 2020). Disponible en: https://www.npr.org/sections/healthshots/2020/06/29/884648842/remdesivir-priced-atmore-than-3-100-for-a-course-of-treatment

Marina AM, Jaime KJ, Consuelo MB, Francisco LN, Manuel MNJ. Las enfermedades “olvidadas” de América Latina y el Caribe: un problema de salud pública global. Revista mexicana de ciencias farmacéuticas. 2012; 43(1):33-41

López-Medina E, López P, Hurtado IC, Dávalos DM, Ramirez O, Martínez E, et al. Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19 A Randomized Clinical Trial. JAMA. 2021;325(14):1426-1435. https://doi.org/10.1001/jama.2021.3071

Roman YM, Burela PA, Pasupuleti V, Piscoya A, Vidal JE, Hernandez AV. Ivermectin for the Treatment of Coronavirus Disease 2019: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Clin Infect Dis. 2021. https://doi.org/10.1093/cid/ciab591

Cómo citar
(1)
Carlosama-Rosero, Y. H. Criterios Para El Uso E investigación De Medicamentos off-Label Frente Al Covid-19 En Latinoamérica. Rev. Fac. Cienc. Salud Univ. Cauca 2021, 23, 39-46.
Publicado
2021-11-22